News & Events

  • March 02, 2017

    James K. Landau, a member of the Firm, was invited by PLI to participate on a panel discussing the use of social media by attorneys on March 17, 2017.

    Click here for more details

  • February 27, 2017

    Daseke, Inc. and Hennessy Capital Acquisition Corp. II announced the completion of their business combination.  EG&S acted as special SPAC counsel to Hennessy.

  • February 24, 2017

    Arch Therapeutics Inc. announced the closing of their Registered Direct offering in the amount of $6,100,000.  EG&S acted as counsel to the lead Investor.

  • February 23, 2017

    Biopharmaceuticals Ltd. announced the closing of their Registered Direct offering in the amount of $2,500,000.  EG&S acted as counsel to the Placement Agent.

  • February 21, 2017

    Ellenoff Grossman & Schole LLP is proud to announce the addition of a new practice group – Immigration.  John Assadi joins EG&S as a Member and Mauricio Martinez as an Associate.

    Click here to view the announcement

  • February 15, 2017

    Biostage, Inc. announced the closing of their Registered Direct offering in the amount of $8,000,000.  EG&S acted as counsel to the Placement Agent.

  • February 14, 2017

    Moleculin Biotech, Inc. announced the closing of their Underwritten offering in the amount of $4,657,905.  EG&S acted as counsel to the Underwriter.

  • February 10, 2017

    Real Goods Solar, Inc. announced the closing of their Registered Direct offering in the amount of $6,000,000.  EG&S acted as counsel to the Placement Agent.

  • February 07, 2017

    Ellenoff Grossman & Schole LLP is proud to announce the addition of a new attorney in our Corporate department.  His name is Jeffrey W. Rubin and he joins as a member of the Firm and specializes in corporate, M&A and securities law.

    Click here to read his announcement

  • February 06, 2017

    Real Goods Solar, Inc. announced the closing of their Registered Direct offering in the amount of $11,484,869.  EG&S acted as counsel to the Placement Agent.

  • February 06, 2017

    Hemispherx Biopharma, Inc. announced the closing of their Registered Direct offering in the amount of $1,000,001.  EG&S acted as counsel to the Placement Agent.

  • February 02, 2017

    Rennova Health, Inc. announced the closing of their Registered Direct offering in the amount of $1,500,000. EG&S acted as counsel to the Investor.

  • January 31, 2017

    The Ninth Circuit has dismissed an appeal by a group of shareholders who had accused Cellular Biomedicine Group in a federal class action of inflating its stock price through a promotional scheme.  Plaintiffs chose not to challenge the district court's holding that they could not allege loss causation.

    Adrienne M. Ward and Michael J. Sullivan, both members of the Firm, represented Cellular Biomedicine in the appeal.  Click here to read more on the case.

  • January 30, 2017

    The February 2017 edition of Westchester Lawyer Magazine includes an article by James K. Landau, a member in the Firm’s litigation department, entitled “How to Leverage the Internet and Technology to Sharpen your Appellate Advocacy”.  Mr. Landau is the co-chair of the Westchester County Bar Association’s Committee on Appellate Practice and handles cases involving misappropriation of trade secrets, non-competition clauses in employment agreements and real estate related litigation.  The article can be read here.

  • January 27, 2017

    BioAmber Inc. announced the closing of their Underwritten offering in the amount of $20,125,009.  EG&S acted as counsel to the Underwriter.

  • January 25, 2017

    Fintech Acquisition Corp. II announced the closing of their initial public offering in the amount of $153,000,000.  EG&S acted as counsel to Cantor Fitzgerald.

  • January 24, 2017

    Amedica Corporation announced the closing of their Confidentially Marketed Public Offering in the amount of $4,500,000.  EG&S acted as counsel to Maxim Group.

  • January 24, 2017

    EGS assisted PhotoMedex, Inc. in its sale of substantially all of its assets primarily related to or used in the company’s consumer products division, including its no!no!® hair and skin products and the Kyrobak back pain management products.

    The gross proceeds receivable by the company were up to $5M. In addition, the company entered into a royalty agreement with the purchaser.

  • January 24, 2017

    Can-Fite Biopharma Ltd. announced the closing of their Registered Direct offering in the amount of $5,000,000.  EG&S acted as counsel to the Placement Agent.

  • January 23, 2017

    EnteroMedics, Inc. announced the closing of their Underwritten offering in the amount of $20,125,009.  EG&S acted as counsel to the Underwriter.

  • January 23, 2017

    PURE Bioscience, Inc. announced the closing of their PIPE offering in the amount of $5,000,000.  EG&S acted as counsel to the Placement Agent.

  • January 20, 2017

    Uranium Energy Corp. announced the closing of their Underwritten offering in the amount of $25,996,254.  EG&S acted as counsel to the Underwriter.

  • January 11, 2017

    Sequel Youth and Family Services and Global Partner Acquisition Corp. announce agreement for business combination.  EG&S acted as special SPAC counsel to Global Partner Acquisition.

  • January 09, 2017

    OurCrowd Digital Health L.P., announced the completion of their $5.1Million offering of DarioHealth Corp where they were the lead investor.  EG&S acted as counsel to OurCrowd.

  • January 09, 2017

    OXIS International Inc. announced the closing of their PIPE offering in the amount of $19,821.00.  EG&S acted as counsel to the Placement Agent.